Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Dec
17
Today In Oncology
Flipped Nivolumab/Ipilimumab Dosing Improves Outcomes in Advanced Melanoma
Tanning Bed Exposure and Melanoma Risks
FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
HER2-Positive Breast Cancer FDA Approves T-DXd Plus Pertuzumab
Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo